Literature DB >> 8043524

Cortical cholinergic markers in schizophrenia.

V Haroutunian1, M Davidson, P D Kanof, D P Perl, P Powchik, M Losonczy, J McCrystal, D P Purohit, L M Bierer, K L Davis.   

Abstract

Cortical cholinergic deficits have been implicated in the cognitive deficits produced by a variety of neurodegenerative diseases including Alzheimer's disease (AD). Recent studies have suggested that many of the chronically institutionalized geriatric schizophrenic patients are also cognitively impaired. In this postmortem study we compared cholinergic marker activity in six different cortical regions derived from elderly controls, chronically institutionalized geriatric schizophrenic patients, and AD patients. All of the Alzheimer's disease cases met neuropathological criteria for AD, while none of the schizophrenic cases met criteria for AD. Cholinergic marker activity (choline acetyltransferase and acetylcholinesterase) was significantly diminished in the AD cohort but not in the schizophrenic cohort. Additionally, cortical choline acetyltransferase activity was significantly and negatively correlated with Clinical Dementia Rating scores (CDR), whereas no such correlations were evident in the schizophrenic cohort. These results suggest that cognitive deficits in geriatric schizophrenics are not due to diminished cortical cholinergic activity.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8043524     DOI: 10.1016/0920-9964(94)90071-x

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  6 in total

1.  Abnormalities in the tricarboxylic acid (TCA) cycle in the brains of schizophrenia patients.

Authors:  P Bubber; V Hartounian; G E Gibson; J P Blass
Journal:  Eur Neuropsychopharmacol       Date:  2010-11-30       Impact factor: 4.600

Review 2.  Cholinergic contributions to the cognitive symptoms of schizophrenia and the viability of cholinergic treatments.

Authors:  Martin Sarter; Cindy Lustig; Stephan F Taylor
Journal:  Neuropharmacology       Date:  2010-12-13       Impact factor: 5.250

3.  Mitochondrial enzymes in schizophrenia.

Authors:  Parvesh Bubber; Jicheng Tang; Vahram Haroutunian; Hui Xu; Kenneth L Davis; John P Blass; Gary E Gibson
Journal:  J Mol Neurosci       Date:  2004       Impact factor: 3.444

4.  Lack of association between schizophrenia and the apolipoprotein E epsilon 4 allele.

Authors:  E Jönsson; L Lannfelt; B Engvall; G Sedvall
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1996       Impact factor: 5.270

5.  Cholinergic receptor alterations in the brain stem of spinal cord injured rats.

Authors:  Chinthu Romeo; Anju Thoppil Raveendran; Nandhu Mohan Sobha; Cheramadathukuzhiyil Scaria Paulose
Journal:  Neurochem Res       Date:  2012-11-27       Impact factor: 3.996

Review 6.  Cholinergic circuits and signaling in the pathophysiology of schizophrenia.

Authors:  Joshua A Berman; David A Talmage; Lorna W Role
Journal:  Int Rev Neurobiol       Date:  2007       Impact factor: 3.230

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.